147 related articles for article (PubMed ID: 23448894)
1. New concepts for CML clonality.
Khorashad JS; Deininger MW; O'Hare T
Oncotarget; 2013 Jan; 4(1):7-8. PubMed ID: 23448894
[No Abstract] [Full Text] [Related]
2. Ponatinib circumvents all types of imatinib resistance in chronic myelogenous leukemia cell lines.
Dufies M; Cassuto O; Jacquel A; Robert G; Auberger P
Cell Cycle; 2013 Jun; 12(11):1645-6. PubMed ID: 23673326
[No Abstract] [Full Text] [Related]
3. Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naive patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India.
Kuila N; Dash N; Sahoo DP; Pattnayak NC; Biswas G; Chakraborty S
Leuk Lymphoma; 2009 Apr; 50(4):663-6. PubMed ID: 19373669
[No Abstract] [Full Text] [Related]
4. Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.
Markose P; Chendamarai E; Balasubramanian P; Velayudhan SR; Srivastava VM; Mathews V; George B; Viswabandya A; Srivastava A; Chandy M
Leuk Lymphoma; 2009 Dec; 50(12):2092-5. PubMed ID: 19925053
[No Abstract] [Full Text] [Related]
5. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
6. Ever-advancing chronic myeloid leukemia treatment.
Kimura S; Ando T; Kojima K
Int J Clin Oncol; 2014 Feb; 19(1):3-9. PubMed ID: 24258348
[TBL] [Abstract][Full Text] [Related]
7. As leukemia options grow, drugs jockey to be first-line therapies.
Dolgin E
Nat Med; 2013 Jan; 19(1):7. PubMed ID: 23295994
[No Abstract] [Full Text] [Related]
8. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
O'Hare T; Eide CA; Deininger MW
Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
[TBL] [Abstract][Full Text] [Related]
9. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
[No Abstract] [Full Text] [Related]
10. New drugs for chronic myelogenous leukemia.
Santos FP; Quintás-Cardama A
Curr Hematol Malig Rep; 2011 Jun; 6(2):96-103. PubMed ID: 21327563
[TBL] [Abstract][Full Text] [Related]
11. [Management of advanced stage chronic myeloid leukemia].
Takahashi N
Rinsho Ketsueki; 2014 Oct; 55(10):1860-9. PubMed ID: 25297750
[No Abstract] [Full Text] [Related]
12. Mutations in ABL kinase domain are associated with inferior progression-free survival.
Sharma P; Mohanty S; Kochupillai V; Kumar L
Leuk Lymphoma; 2010 Jun; 51(6):1072-8. PubMed ID: 20367437
[TBL] [Abstract][Full Text] [Related]
13. 10 years of progress in chronic myelogenous leukemia.
Jabbour E; Mathisen MS; O'Brien S
J Natl Compr Canc Netw; 2012 Sep; 10(9):1049-53. PubMed ID: 22956803
[No Abstract] [Full Text] [Related]
14. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
Shah NP; Skaggs BJ; Branford S; Hughes TP; Nicoll JM; Paquette RL; Sawyers CL
J Clin Invest; 2007 Sep; 117(9):2562-9. PubMed ID: 17710227
[TBL] [Abstract][Full Text] [Related]
15. Overcoming resistance in chronic myelogenous leukemia.
Cooper S; Giles FJ; Savona MR
Leuk Lymphoma; 2009 Nov; 50(11):1785-93. PubMed ID: 19883308
[TBL] [Abstract][Full Text] [Related]
16. ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis.
Sacha T; Hochhaus A; Hanfstein B; Müller MC; Rudzki Z; Czopek J; Wolska-Smoleń T; Czekalska S; Salamanchuk Z; Jakóbczyk M; Skotnicki AB
Leuk Res; 2003 Dec; 27(12):1163-6. PubMed ID: 12921956
[TBL] [Abstract][Full Text] [Related]
17. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Shah NP; Nicoll JM; Nagar B; Gorre ME; Paquette RL; Kuriyan J; Sawyers CL
Cancer Cell; 2002 Aug; 2(2):117-25. PubMed ID: 12204532
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance to BCR-ABL and other kinase inhibitors.
Lamontanara AJ; Gencer EB; Kuzyk O; Hantschel O
Biochim Biophys Acta; 2013 Jul; 1834(7):1449-59. PubMed ID: 23277196
[TBL] [Abstract][Full Text] [Related]
19. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
20. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
Wu J; Meng F; Lu H; Kong L; Bornmann W; Peng Z; Talpaz M; Donato NJ
Blood; 2008 Apr; 111(7):3821-9. PubMed ID: 18235045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
